=0.004)。Logistic回归模型曲线下面积(area under curve,AUC)为0.67,且该模型校准性能良好且具有一定临床实用性。以7∶3划分后,训练组纳入111例患者(低危组34例,高危组77例),验证组纳入48例患者(低危组和高危组均为24例)。4种机器学习模型AUC为0.64~0.69,支持向量机和随机森林模型预
测效能相对较高。
结论:
MRI在评估ER
+
/HER
-
乳腺癌患者复发风险方面具有潜在价值。
Abstract
Objective:
To explore the association between magnetic resonance imaging (MRI) features and the 21-gene recurrence score (RS)
and to establish RS prediction models.
Methods:
Clinical and imaging data of estrogen receptor (ER)
+
/ human epidermal growth factor receptor 2 (HER2)
-
breast cancer patients who underwent 21-gene expression assay in Fudan University Shanghai Cancer Center from April 2017 to March 2019 were collected. The patients who underwent preoperative breast MRI were selected. MRI images were evaluated according to the 2013 version of Breast Imaging Reporting and Data System lexicon. The univariate analyses were used to compare differences in MRI imaging features between the high-risk group (RS≥26) and the low-risk group (RS<26) and multivariate logistic regression was used to construct a model. The patients were divided into the training group and the validation group in a 7∶3 ratio. Pearson correlation coefficient screening method and recursive feature elimination method were used for feature screening
the synthetic minority oversampling technique was used for balancing the training dataset
four different machine learning algorithms (linear support vector machine
random forest
decision tree and K-nearest neighbor) were used to construct the models
and the model performance was evaluated by receiver operating characteristic (ROC) curve.
Results:
A total of 159 patients were enrolled
with 58 in the low-risk group and 101 in the high-risk group. In clinical characteristics
progesterone receptor (PR) status showed difference (
P
=0.017)
and the proportion of patients with positive PR expression was higher in the low- risk group than in the high-risk group. In the MRI characteristics
the distribution of tumor margins showed difference between groups
(
P
=0.008). The tumors in the low-risk group were mostly characterized by spiculated margins (64.8%)
and the tumors in the high-risk group were mostly characterized by irregular margins (54.7%). Incorporating PR status and tumor margin into the multivariate logistic regression model
PR positive patients had a lower risk of recurrence than PR negative patients
with an OR value of 0.110 (
P
=0.038); the recurrence risk of spiculated margins was relatively lower than that of irregular margins
with an OR value of 0.343 (
P
=0.004). The area under curve (AUC) was 0.667. The calibration curve and decision curve indicated that the model had good calibration performance and certain clinical practicability. 111 patients were included in the training group (34 in low- risk group and 77 in high-risk group) and 48 patients were included in the validation group (24 in low-risk group and 24 in high-risk group). The AUC range of the four machine learning models was 0.64-0.69
and the AUCs of support vector machine and random forest models were relatively higher.
Conclusion:
Breast MRI features have a potential role in assessing the recurrence risk of ER
Prediction of sentinel lymph node metastasis in breast cancer using multiparametric MRI radiomics and machine learning models
The progress of breast MRI in evaluating breast conservation therapy and ipsilateral breast tumor recurrence
Prediction value of breast MRI in ipsilateral breast tumor recurrence after breast-conserving surgery and distant metastasis following secondary surgery
Development of a nomogram for differentiation between pure mucinous breast carcinomas and fibroadenomas based on DCE-MRI features
The diagnostic value of MRI in solid papillary carcinoma
Related Author
Hongkai YANG
Xuan QI
Wuling WANG
Weiqun CHENG
Dong QI
Yongsheng HE
LI Jinhui
YOU Chao
Related Institution
Department of Radiology, Ma’anshan People’s Hospital, Ma’anshan
The Graduate School, Anhui Medical University
The Fifth Clinical Medical College of Anhui Medical University
Department of Radiology, Fudan University Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Breast Surgery, Fudan University Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University